Related references
Note: Only part of the references are listed.Siponimod Inhibits the Formation of Meningeal Ectopic Lymphoid Tissue in Experimental Autoimmune Encephalomyelitis
Rosa Margareta Brand et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2022)
Anti-CD20 Disrupts Meningeal B-Cell Aggregates in a Model of Secondary Progressive Multiple Sclerosis
Jay Roodselaar et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2021)
Anti-CD20 Depletes Meningeal B Cells but Does Not Halt the Formation of Meningeal Ectopic Lymphoid Tissue
Rosa Margareta Brand et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2021)
Comparative efficacy and acceptability of disease-modifying therapies in patients with relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis
Huihui Li et al.
JOURNAL OF NEUROLOGY (2020)
Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial
Jerry S. Wolinsky et al.
LANCET NEUROLOGY (2020)
B Cells in Multiple Sclerosis and Virus-Induced Neuroinflammation
Rittika Chunder et al.
FRONTIERS IN NEUROLOGY (2020)
Trial of intrathecal rituximab in progressive multiple sclerosis patients with evidence of leptomeningeal contrast enhancement
Pavan Bhargava et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2019)
The Role of B Cells and Antibodies in Multiple Sclerosis, Neuromyelitis Optica, and Related Disorders
Silke Haeusser-Kinzel et al.
FRONTIERS IN IMMUNOLOGY (2019)
MRI of cortical lesions and its use in studying their role in MS pathogenesis and disease course
R. Magliozzi et al.
BRAIN PATHOLOGY (2018)
Reassessing B cell contributions in multiple sclerosis
Rui Li et al.
NATURE IMMUNOLOGY (2018)
Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis The MIRROR study
Amit Bar-Or et al.
NEUROLOGY (2018)
B cells are capable of independently eliciting rapid reactivation of encephalitogenic CD4 T cells in a murine model of multiple sclerosis
Chelsea R. Parker Harp et al.
PLOS ONE (2018)
Clinical Course of Multiple Sclerosis
Sylvia Klineova et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2018)
Multiple Sclerosis Pathology
Hans Lassmann
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2018)
Anti-CD52 antibody treatment depletes B cell aggregates in the central nervous system in a mouse model of multiple sclerosis
Micha Simon et al.
JOURNAL OF NEUROINFLAMMATION (2018)
Functional characterization of reappearing B cells after anti-CD20 treatment of CNS autoimmune disease
Darius Haeusler et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
Anti-CD20 monoclonal antibodies: reviewing a revolution
J. M. L. Casan et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2018)
B cells from patients with multiple sclerosis. induce cell death via apoptosis in neurons in vitro
Robert P. Lisak et al.
JOURNAL OF NEUROIMMUNOLOGY (2017)
Differential effects of FTY720 on the B cell compartment in a mouse model of multiple sclerosis
Kathrin Bail et al.
JOURNAL OF NEUROINFLAMMATION (2017)
Ocrelizumab and Other CD20+ B-Cell-Depleting Therapies in Multiple Sclerosis
Jeffrey M. Gelfand et al.
NEUROTHERAPEUTICS (2017)
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
S. L. Hauser et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
X. Montalban et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Obinutuzumab for the First-Line Treatment of Follicular Lymphoma
R. Marcus et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Rituximab in multiple sclerosis A retrospective observational study on safety and efficacy
Jonatan Salzer et al.
NEUROLOGY (2016)
Insufficient disease inhibition by intrathecal rituximab in progressive multiple sclerosis
Mika Komori et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2016)
Central nervous system infiltrates are characterized by features of ongoing B cell-related immune activity in MP4-induced experimental autoimmune encephalomyelitis
Helena Batoulis et al.
CLINICAL IMMUNOLOGY (2015)
Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study
V. Goede et al.
LEUKEMIA (2015)
The Immunogenicity of Antibody Aggregates in a Novel Transgenic Mouse Model
Juliana Bessa et al.
PHARMACEUTICAL RESEARCH (2015)
Regional Distribution and Evolution of Gray Matter Damage in Different Populations of Multiple Sclerosis Patients
Massimiliano Calabrese et al.
PLOS ONE (2015)
Obinutuzumab (GA101) for the Treatment of Chronic Lymphocytic Leukemia and Other B-Cell Non-Hodgkin's Lymphomas: A Glycoengineered Type II CD20 Antibody
Valentin Goede et al.
ONCOLOGY RESEARCH AND TREATMENT (2015)
Immunopathology of multiple sclerosis
Calliope A. Dendrou et al.
NATURE REVIEWS IMMUNOLOGY (2015)
Glycoengineering of Therapeutic Antibodies Enhances Monocyte/Macrophage-Mediated Phagocytosis and Cytotoxicity
Sylvia Herter et al.
JOURNAL OF IMMUNOLOGY (2014)
Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis A phase 2 study
Per S. Sorensen et al.
NEUROLOGY (2014)
Defining the clinical course of multiple sclerosis The 2013 revisions
Fred D. Lublin et al.
NEUROLOGY (2014)
Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions
Valentin Goede et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Environmental Factors and Multiple Sclerosis Severity: A Descriptive Study
Daniele Mandia et al.
INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH (2014)
A Single Dose of Rituximab Does Not Deplete B Cells in Secondary Lymphoid Organs but Alters Phenotype and Function
E. G. Kamburova et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2013)
Incidence and prevalence of multiple sclerosis in Europe: a systematic review
Elaine Kingwell et al.
BMC NEUROLOGY (2013)
MHC class II-dependent B cell APC function is required for induction of CNS autoimmunity independent of myelin-specific antibodies
Nicolas Molnarfi et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab In Vitro and in Xenograft Models
Sylvia Herter et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties
Christian Klein et al.
MABS (2013)
Relapsing-remitting and primary progressive MS have the same cause(s)-the neuropathologist's view: 2
Tanja Kuhlmann
MULTIPLE SCLEROSIS JOURNAL (2013)
B-cell subpopulations in humans and their differential susceptibility to depletion with anti-CD20 monoclonal antibodies
Maria J. Leandro
ARTHRITIS RESEARCH & THERAPY (2013)
Marginal zone B cells: virtues of innate-like antibody-producing lymphocytes
Andrea Cerutti et al.
NATURE REVIEWS IMMUNOLOGY (2013)
Tertiary lymphoid organ development coincides with determinant spreading of the myelin-specific T cell response
Stefanie Kuerten et al.
ACTA NEUROPATHOLOGICA (2012)
Secretory products of multiple sclerosis B cells are cytotoxic to oligodendroglia in vitro
Robert P. Lisak et al.
JOURNAL OF NEUROIMMUNOLOGY (2012)
MS and the B cell controversy
Anne H. Cross et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2011)
Effect of B-cell depletion using anti-CD20 therapy on inhibitory antibody formation to human FVIII in hemophilia A mice
Ai-Hong Zhang et al.
BLOOD (2011)
Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies
Gerhard Niederfellner et al.
BLOOD (2011)
Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis
Owain W. Howell et al.
BRAIN (2011)
Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS)
Cris S. Constantinescu et al.
BRITISH JOURNAL OF PHARMACOLOGY (2011)
Preclinical Studies on the Mechanism of Action and the Anti-Lymphoma Activity of the Novel Anti-CD20 Antibody GA101
Stephane Dalle et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial
Ludwig Kappos et al.
LANCET (2011)
Heterogeneity in Multiple Sclerosis: Scratching the Surface of a Complex Disease
Giulio Disanto et al.
AUTOIMMUNE DISEASES (2011)
B-Cell Activation Influences T-Cell Polarization and Outcome of Anti-CD20 B-Cell Depletion in Central Nervous System Autoimmunity
Martin S. Weber et al.
ANNALS OF NEUROLOGY (2010)
A Gradient of Neuronal Loss and Meningeal Inflammation in Multiple Sclerosis
Roberta Magliozzi et al.
ANNALS OF NEUROLOGY (2010)
Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity
Ekkehard Moessner et al.
BLOOD (2010)
T cells in multiple sclerosis and experimental autoimmune encephalomyelitis
J. M. Fletcher et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2010)
Chronic Progressive Multiple Sclerosis - Pathogenesis of Neurodegeneration and Therapeutic Strategies
Dirk Fitzner et al.
CURRENT NEUROPHARMACOLOGY (2010)
Improving Bioscience Research Reporting: The ARRIVE Guidelines for Reporting Animal Research
Carol Kilkenny et al.
PLOS BIOLOGY (2010)
The relation between inflammation and neurodegeneration in multiple sclerosis brains
Josa M. Frischer et al.
BRAIN (2009)
Fundamental differences in the dynamics of CNS lesion development and composition in MP4-and MOG peptide 35-55-induced experimental autoimmune encephalomyelitis
Stefanie Kuerten et al.
CLINICAL IMMUNOLOGY (2008)
B-cell depletion with Rituximab in relapsing-remitting multiple sclerosis
Stephen L. Hauser et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Cerebrospinal Fluid B Cells Correlate with Early Brain Inflammation in Multiple Sclerosis
Bettina Kuenz et al.
PLOS ONE (2008)
Maintenance of long-lived plasma cells and serological memory despite mature and memory B cell depletion during CD20 immunotherapy in mice
David J. DiLillo et al.
JOURNAL OF IMMUNOLOGY (2008)
Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology
Roberta Magliozzi et al.
BRAIN (2007)
Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research
Ralf Gold et al.
BRAIN (2006)
Cortical demyelination and diffuse white matter injury in multiple sclerosis
A Kutzelnigg et al.
BRAIN (2005)
Pathogenesis of multiple sclerosis
A Prat et al.
CURRENT OPINION IN NEUROLOGY (2005)
Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy
Q Gong et al.
JOURNAL OF IMMUNOLOGY (2005)
Rat and human myelin oligodendrocyte glycoproteins induce experimental autoimmune encephalomyelitis by different mechanisms in C57BL/6 mice
AR Oliver et al.
JOURNAL OF IMMUNOLOGY (2003)
Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts
MS Cragg et al.
BLOOD (2003)
Effective B cell depletion with rituximab in the treatment of autoimmune diseases
C Kneitz et al.
IMMUNOBIOLOGY (2002)
Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis
C Lock et al.
NATURE MEDICINE (2002)
Share Paper
